Kamada (KMDA) said Wednesday it opened a new plasma collection center in San Antonio, Texas, with an expected annual collection capacity of about 50,000 liters.
The plasma-derived protein therapeutics manufacturer said the new facility will collect normal source plasma for third-party sales and specialty plasma, including Anti-Rabies and Anti-D, for internal use.
The company said it expects sales of normal source plasma from the site to generate $8 million to $10 million annually at full capacity.
Kamada said it plans to seek regulatory approvals for the new site from the US Food and Drug Administration and the European Medicines Agency in H2.
Price: 6.69, Change: +0.03, Percent Change: +0.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。